Concepedia

Author

Joseph M. Luettgen

Bristol-Myers Squibb (United States)ORCID

Also Known As

Alan Rendina, J Luettgen, J.M. LUETTGEN, J.M. Luettgen, Joseph Luettgen, Joseph M Luettgen, Joseph M. Luettgen, Luettgen, Joseph M.

92

Publications

3.6K

Citations

33

H-Index

38

Concepts

All Affiliations

Bristol-Myers Squibb (United States)Bristol-Myers Squibb (Germany)Bristol-Myers Squibb (Sweden)DuPont (United States)Experimental Station
JM

About

Joseph M. Luettgen is an author at Bristol-Myers Squibb (United States) specializing in pharmacology, medicine, and drug discovery.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

27

48

2.4K

2

Natural Sciences

22

31

1.5K

3

Biochemistry

22

32

1.6K

4

Biomolecular Engineering

4

4

271

5

Health Sciences

1

1

42

Joseph M. Luettgen

×

66

Publications

3.2K

Citations

31

H-Index

YearCitations

Discovery of 1-(4-Methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro- 1<i>H</i>-pyrazolo[3,4-<i>c</i>]pyridine-3-carboxamide (Apixaban, BMS-562247), a Highly Potent, Selective, Efficacious, and Orally Bioavailable Inhibitor of Blood Coagulation Factor Xa

Donald Pinto, Michael J. Orwat, Stephanie C. Koch,

Journal of Medicinal Chemistry

2007

391

Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies

Pancras C. Wong, Earl J. Crain, Bailong Xin,

Journal of Thrombosis and Haemostasis

2008

299

Discovery of 1-(3‘-Aminobenzisoxazol-5‘-yl)-3-trifluoromethyl-<i>N</i>-[2-fluoro-4- [(2‘-dimethylaminomethyl)imidazol-1-yl]phenyl]-1<i>H</i>-pyrazole-5-carboxyamide Hydrochloride (Razaxaban), a Highly Potent, Selective, and Orally Bioavailable Factor Xa Inhibitor

Mimi L. Quan, Patrick Y. S. Lam, Qi Han,

Journal of Medicinal Chemistry

2004

188

Discovery of 1-[3-(Aminomethyl)phenyl]-<i>N</i>-[3-fluoro-2‘-(methylsulfonyl)- [1,1‘-biphenyl]-4-yl]-3-(trifluoromethyl)-1<i>H</i>-pyrazole-5-carboxamide (DPC423), a Highly Potent, Selective, and Orally Bioavailable Inhibitor of Blood Coagulation Factor Xa

Donald Pinto, Michael J. Orwat, Shuaige Wang,

Journal of Medicinal Chemistry

2001

172

Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor

Kan He, Joseph M. Luettgen, Donglu Zhang,

European Journal of Drug Metabolism and Pharmacokinetics

2011

95

Structure-Based Design of Novel Guanidine/Benzamidine Mimics:  Potent and Orally Bioavailable Factor Xa Inhibitors as Novel Anticoagulants

Patrick Y. S. Lam, Charles G. Clark, Renhua Li,

Journal of Medicinal Chemistry

2003

95

Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic Therapy

Andrew K. Dilger, Kumar B. Pabbisetty, James R. Corte,

Journal of Medicinal Chemistry

2021

93

First‐in‐human study of milvexian, an oral, direct, small molecule factor XIa inhibitor

Vidya Perera, Zhaoqing Wang, Joseph M. Luettgen,

Clinical and Translational Science

2021

86

Tetrahydroquinoline Derivatives as Potent and Selective Factor XIa Inhibitors

Mimi L. Quan, Pancras C. Wong, Cailan Wang,

Journal of Medicinal Chemistry

2014

76

Discovery of 1-(2-Aminomethylphenyl)-3-trifluoromethyl-<i>N</i>- [3-fluoro-2‘-(aminosulfonyl)[1,1‘-biphenyl)]-4-yl]-1<i>H</i>-pyrazole-5-carboxyamide (DPC602), a Potent, Selective, and Orally Bioavailable Factor Xa Inhibitor

James R. Pruitt, Donald Pinto, Robert A. Galemmo,

Journal of Medicinal Chemistry

2003

75

Page 1